First-line bevacizumab-containing therapy for breast cancer

Results in patients aged ≥70 years treated in the ATHENA study

L. Biganzoli, E. Di Vincenzo, Z. Jiang, M. Lichinitser, Z. Shen, R. Delva, N. Bogdanova, G. L. Vivanco, Z. Chen, Y. Cheng, M. Just, M. Espié, J. Vinholes, C. Hamm, D. Crivellari, E. Chmielowska, V. Semiglazov, F. Dalenc, I. Smith

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice. Patients and methods: Patients with human epidermal growth factor receptor-2-negative LR/mBC received firstline bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We carried out a subgroup analysis of safety and efficacy in patients aged ≥70 years. Possible correlations between tolerability and baseline comorbidities or Eastern Cooperative Oncology Group status were explored. Results: Bevacizumab was combined with single-agent paclitaxel in 46% of older patients. Only hypertension and proteinuria were more common in older than in younger patients (grade ≥3 hypertension: 6.9% versus 4.2%, respectively; grade ≥3 proteinuria: 4.0% versus 1.5%, respectively). Grade ≥3 arterial/venous thromboembolism occurred in 2.9% versus 3.3%, respectively. Further analysis revealed no relationship between baseline presence and severity of hypertension and risk of developing hypertension during bevacizumab-containing therapy. Median time to progression was 10.4 months in patients aged ≥70 years. Conclusions: These findings suggest that bevacizumab-containing therapy is tolerable and active in patients aged ≥70 years. Hypertension was more common than in younger patients but was manageable. We find no evidence precluding the use of bevacizumab in older patients, including those with hypertension, although age may influence chemotherapy choice.

Original languageEnglish
Article numbermdr043
Pages (from-to)111-118
Number of pages8
JournalAnnals of Oncology
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Breast Neoplasms
Hypertension
Therapeutics
Proteinuria
Drug Therapy
Bevacizumab
Venous Thromboembolism
Paclitaxel
Disease Progression
Comorbidity
Physicians
Safety
Population

Keywords

  • Bevacizumab
  • Comorbidity
  • Elderly
  • First line
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Biganzoli, L., Di Vincenzo, E., Jiang, Z., Lichinitser, M., Shen, Z., Delva, R., ... Smith, I. (2012). First-line bevacizumab-containing therapy for breast cancer: Results in patients aged ≥70 years treated in the ATHENA study. Annals of Oncology, 23(1), 111-118. [mdr043]. https://doi.org/10.1093/annonc/mdr043

First-line bevacizumab-containing therapy for breast cancer : Results in patients aged ≥70 years treated in the ATHENA study. / Biganzoli, L.; Di Vincenzo, E.; Jiang, Z.; Lichinitser, M.; Shen, Z.; Delva, R.; Bogdanova, N.; Vivanco, G. L.; Chen, Z.; Cheng, Y.; Just, M.; Espié, M.; Vinholes, J.; Hamm, C.; Crivellari, D.; Chmielowska, E.; Semiglazov, V.; Dalenc, F.; Smith, I.

In: Annals of Oncology, Vol. 23, No. 1, mdr043, 01.2012, p. 111-118.

Research output: Contribution to journalArticle

Biganzoli, L, Di Vincenzo, E, Jiang, Z, Lichinitser, M, Shen, Z, Delva, R, Bogdanova, N, Vivanco, GL, Chen, Z, Cheng, Y, Just, M, Espié, M, Vinholes, J, Hamm, C, Crivellari, D, Chmielowska, E, Semiglazov, V, Dalenc, F & Smith, I 2012, 'First-line bevacizumab-containing therapy for breast cancer: Results in patients aged ≥70 years treated in the ATHENA study', Annals of Oncology, vol. 23, no. 1, mdr043, pp. 111-118. https://doi.org/10.1093/annonc/mdr043
Biganzoli, L. ; Di Vincenzo, E. ; Jiang, Z. ; Lichinitser, M. ; Shen, Z. ; Delva, R. ; Bogdanova, N. ; Vivanco, G. L. ; Chen, Z. ; Cheng, Y. ; Just, M. ; Espié, M. ; Vinholes, J. ; Hamm, C. ; Crivellari, D. ; Chmielowska, E. ; Semiglazov, V. ; Dalenc, F. ; Smith, I. / First-line bevacizumab-containing therapy for breast cancer : Results in patients aged ≥70 years treated in the ATHENA study. In: Annals of Oncology. 2012 ; Vol. 23, No. 1. pp. 111-118.
@article{0e37b1ce225444d8976fd0751f6d9894,
title = "First-line bevacizumab-containing therapy for breast cancer: Results in patients aged ≥70 years treated in the ATHENA study",
abstract = "Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice. Patients and methods: Patients with human epidermal growth factor receptor-2-negative LR/mBC received firstline bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We carried out a subgroup analysis of safety and efficacy in patients aged ≥70 years. Possible correlations between tolerability and baseline comorbidities or Eastern Cooperative Oncology Group status were explored. Results: Bevacizumab was combined with single-agent paclitaxel in 46{\%} of older patients. Only hypertension and proteinuria were more common in older than in younger patients (grade ≥3 hypertension: 6.9{\%} versus 4.2{\%}, respectively; grade ≥3 proteinuria: 4.0{\%} versus 1.5{\%}, respectively). Grade ≥3 arterial/venous thromboembolism occurred in 2.9{\%} versus 3.3{\%}, respectively. Further analysis revealed no relationship between baseline presence and severity of hypertension and risk of developing hypertension during bevacizumab-containing therapy. Median time to progression was 10.4 months in patients aged ≥70 years. Conclusions: These findings suggest that bevacizumab-containing therapy is tolerable and active in patients aged ≥70 years. Hypertension was more common than in younger patients but was manageable. We find no evidence precluding the use of bevacizumab in older patients, including those with hypertension, although age may influence chemotherapy choice.",
keywords = "Bevacizumab, Comorbidity, Elderly, First line, Metastatic breast cancer",
author = "L. Biganzoli and {Di Vincenzo}, E. and Z. Jiang and M. Lichinitser and Z. Shen and R. Delva and N. Bogdanova and Vivanco, {G. L.} and Z. Chen and Y. Cheng and M. Just and M. Espi{\'e} and J. Vinholes and C. Hamm and D. Crivellari and E. Chmielowska and V. Semiglazov and F. Dalenc and I. Smith",
year = "2012",
month = "1",
doi = "10.1093/annonc/mdr043",
language = "English",
volume = "23",
pages = "111--118",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - First-line bevacizumab-containing therapy for breast cancer

T2 - Results in patients aged ≥70 years treated in the ATHENA study

AU - Biganzoli, L.

AU - Di Vincenzo, E.

AU - Jiang, Z.

AU - Lichinitser, M.

AU - Shen, Z.

AU - Delva, R.

AU - Bogdanova, N.

AU - Vivanco, G. L.

AU - Chen, Z.

AU - Cheng, Y.

AU - Just, M.

AU - Espié, M.

AU - Vinholes, J.

AU - Hamm, C.

AU - Crivellari, D.

AU - Chmielowska, E.

AU - Semiglazov, V.

AU - Dalenc, F.

AU - Smith, I.

PY - 2012/1

Y1 - 2012/1

N2 - Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice. Patients and methods: Patients with human epidermal growth factor receptor-2-negative LR/mBC received firstline bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We carried out a subgroup analysis of safety and efficacy in patients aged ≥70 years. Possible correlations between tolerability and baseline comorbidities or Eastern Cooperative Oncology Group status were explored. Results: Bevacizumab was combined with single-agent paclitaxel in 46% of older patients. Only hypertension and proteinuria were more common in older than in younger patients (grade ≥3 hypertension: 6.9% versus 4.2%, respectively; grade ≥3 proteinuria: 4.0% versus 1.5%, respectively). Grade ≥3 arterial/venous thromboembolism occurred in 2.9% versus 3.3%, respectively. Further analysis revealed no relationship between baseline presence and severity of hypertension and risk of developing hypertension during bevacizumab-containing therapy. Median time to progression was 10.4 months in patients aged ≥70 years. Conclusions: These findings suggest that bevacizumab-containing therapy is tolerable and active in patients aged ≥70 years. Hypertension was more common than in younger patients but was manageable. We find no evidence precluding the use of bevacizumab in older patients, including those with hypertension, although age may influence chemotherapy choice.

AB - Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice. Patients and methods: Patients with human epidermal growth factor receptor-2-negative LR/mBC received firstline bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We carried out a subgroup analysis of safety and efficacy in patients aged ≥70 years. Possible correlations between tolerability and baseline comorbidities or Eastern Cooperative Oncology Group status were explored. Results: Bevacizumab was combined with single-agent paclitaxel in 46% of older patients. Only hypertension and proteinuria were more common in older than in younger patients (grade ≥3 hypertension: 6.9% versus 4.2%, respectively; grade ≥3 proteinuria: 4.0% versus 1.5%, respectively). Grade ≥3 arterial/venous thromboembolism occurred in 2.9% versus 3.3%, respectively. Further analysis revealed no relationship between baseline presence and severity of hypertension and risk of developing hypertension during bevacizumab-containing therapy. Median time to progression was 10.4 months in patients aged ≥70 years. Conclusions: These findings suggest that bevacizumab-containing therapy is tolerable and active in patients aged ≥70 years. Hypertension was more common than in younger patients but was manageable. We find no evidence precluding the use of bevacizumab in older patients, including those with hypertension, although age may influence chemotherapy choice.

KW - Bevacizumab

KW - Comorbidity

KW - Elderly

KW - First line

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=80052428282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052428282&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr043

DO - 10.1093/annonc/mdr043

M3 - Article

VL - 23

SP - 111

EP - 118

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

M1 - mdr043

ER -